Experienced in Sideroblastic Anemia

Dr. Sophie M. Lanzkron

Hematology
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
Accepting New Patients
Experienced in Sideroblastic Anemia
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sophie Lanzkron is a Hematologist in Philadelphia, Pennsylvania. Dr. Lanzkron is rated as an Experienced provider by MediFind in the treatment of Sideroblastic Anemia. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Lanzkron is currently accepting new patients.

Her clinical research consists of co-authoring 165 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Biological, Other
Study Drug: Red Blood Cell
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizuamb
Study Phase: Phase 2
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Other, Drug
Study Drug: SHP655
Study Phase: Phase 1
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: Riociguat
Study Phase: Phase 2
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: May 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

165 Total Publications

Impact of disease- and race-based discrimination in healthcare on pain outcomes among adults living with sickle cell disease in the United States: The mediating roles of internalized stigma and depressive symptoms.
Impact of disease- and race-based discrimination in healthcare on pain outcomes among adults living with sickle cell disease in the United States: The mediating roles of internalized stigma and depressive symptoms.
Journal: Stigma and health
Published: August 26, 2025
Similar Doctors
Advanced in Sideroblastic Anemia
Dr. Robert Slease
Hematology
Advanced in Sideroblastic Anemia
Dr. Robert Slease
Hematology
4701 Ogletown Stanton Rd, Ste 4200, 
Newark, DE 
 (32.8 miles away)
302-737-7700
Languages Spoken:
English
See accepted insurances

Robert Slease is a Hematologist in Newark, Delaware. Dr. Slease is rated as an Advanced provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Sezary Syndrome, Sideroblastic Anemia, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome.

Advanced in Sideroblastic Anemia
Dr. Michael M. Mikhail
Oncology | Hematology
Advanced in Sideroblastic Anemia
Dr. Michael M. Mikhail
Oncology | Hematology

Christiana Care Health Services Inc

4701 Ogletown Stanton Rd, 
Newark, DE 
 (32.8 miles away)
302-623-3605
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Mikhail is an Oncologist and a Hematologist in Newark, Delaware. Dr. Mikhail is rated as a Distinguished provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Paget Disease of the Breast, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Thrombocytopenia. Dr. Mikhail is currently accepting new patients.

Advanced in Sideroblastic Anemia
Dr. Michael W. Lankiewicz
Hematology
Advanced in Sideroblastic Anemia
Dr. Michael W. Lankiewicz
Hematology
4701 Ogletown Stanton Rd, Suite 4200, 
Newark, DE 
 (32.8 miles away)
302-454-9830
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Michael Lankiewicz is a Hematologist in Newark, Delaware. Dr. Lankiewicz is rated as a Distinguished provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Heyde Syndrome, Von Willebrand Disease (VWD), Aplastic Anemia, Pulmonary Embolism, and Bone Marrow Aspiration. Dr. Lankiewicz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lanzkron's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile